Eli Lilly and Co. is buying Verve Therapeutics Inc. and its gene-editing program for about $1.3 billion. Two of the one-time treatments are in the clinic. Lead candidate VERVE-102, a gene-editing ...

The Department of Health and Human Services is allegedly denying clinical trial funding for biotechs based on their ties to ...

With a backdrop of mounting industry disruption and transition, Pharm Exec’s latest listing of the top global biopharma sales ...

The mayor hasn’t said what she’ll do if lawmakers again reject her plan to shield homeowners by raising property taxes on ...

Pharmaceutical giant Eli Lilly shows how they used GitHub to build a better developer environment and increase speed to delivery. Skip to content. Navigation Menu ... I wanted to highlight this first, ...

Eli Lilly isn't a one-trick pony. The company's lineup of approved medicines features blockbusters like Verzenio, a cancer ...

Beyond current successes, Eli Lilly is innovating with a potential game-changing oral GLP-1, orforglipron. Read why I ...

The firm highlighted Eli Lilly's metabolic portfolio developments, noting that the pharmaceutical company quickly provided new information to investors shortly after releasing its ACHIEVE-1 data.

Eli Lilly's growth is impressive, but its current valuation is only justifiable with sustained high growth. Click here to find out why LLY stock is a Hold.

The acquisition aligns with Eli Lilly’s broader diversification strategy beyond its core diabetes and obesity treatment portfolio. Verve’s innovative gene-editing technology, which permanently ...